With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...

In a series of moves by Switzerland-headquartered CDMOs this week, manufacturing powerhouse Lonza is doubling down on its US ...

In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark ...

As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.

Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...

Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...

Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer ...

In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...

Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...

They are putting AI, genomics and new models of care to work in ways that make medicine more precise, useful and accessible.

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...

Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar ...